All News

Found 184 articles

• Schrödinger Announces Closing of Initial Public Offering

  2/10/2020

  Schrödinger, Inc. announced the closing of its initial public offering of 13,664,704 shares of common stock at a public offering price of $17.00 per share, which includes 1,782,352 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for total gross proceeds of approximately $232.3 million, before underwriting discounts and commissions and offering expenses payable by the Company.

• Schrödinger Announces Pricing of Initial Public Offering at $17.00 per share

  2/6/2020

  Schrödinger, Inc. announced the pricing of its initial public offering of 11,882,352 shares of common stock at a public offering price of $17.00 per share, for total gross proceeds of approximately $202.0 million, before underwriting discounts and commissions and offering expenses payable by the Company.

• Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery

  1/8/2020

  Schrödinger and Bayer (BAYN: DE) today announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative high-quality drugs.

• Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company’s Tyk2 Subsidiary      

  12/17/2019

  Nimbus Therapeutics announced the promotion of Chief Medical Officer, Annie C. Chen, M.D., MPH, to President of the company’s Tyk2 subsidiary, Nimbus Lakshmi, Inc.

• 

  Disc Medicine Closes $50 Million Series A and Inks Licensing Deal with AbbVie

  10/29/2019

  Disc Medicine is focused on hepcidin biology to restore red blood cell production in hematologic diseases.

• Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production

  10/29/2019

  Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, announced the completion of a $50 million Series A financing.

• Schrödinger Appoints Drug Discovery Veteran Nancy Thornberry to Board of Directors

  9/24/2019

  Schrödinger announced the appointment of Nancy Thornberry, a biotech executive recognized for her extensive track record in drug discovery and development, to its Board of Directors.

• 

  BioSpace Movers & Shakers, Sept. 20

  9/20/2019

  Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments.

• Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team

  9/19/2019

  Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced that it has appointed Christine Loh, Ph.D., as Senior Vice President, Head of Biology.

• Schrödinger Announces Expansion of Multi-Target Research Collaboration with Takeda and Achievement of First Significant Preclinical Milestone in Lead Program

  9/5/2019

  Schrödinger announced the expansion of its multi-year, multi-target drug discovery collaboration with Takeda, as well as Schrödinger’s achievement of the first significant preclinical milestone for the collaboration’s most advanced program.

• Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery

  9/4/2019

  Schrödinger announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.

• Schrödinger and Qu & Co Announce Collaboration to Advance Quantum Mechanical Computations on Quantum Computers

  9/3/2019

  Schrödinger and Qu & Co announced a business and scientific collaboration to advance the use of quantum mechanics on complex molecular systems using quantum computing hardware.

• Schrödinger Expands Drug Discovery Partnership with Morphic Therapeutic

  8/13/2019

  Extended collaboration leveraging Schrödinger’s computational platform includes new terms with increased and additional milestone payments to Schrödinger

• Schrödinger Appoints Veteran Pharma Financial Leader Gary Sender to Board of Directors

  8/5/2019

  Mr. Sender brings over 30 years of financial leadership experience, with a strong track record of success.

• 

  AbbVie Dives into STING and Boehringer Ingelheim Snaps Up Swiss-based AMAL

  7/15/2019

  The M&A moves are expected to increase the oncology pipelines of both companies.

• Schrödinger Receives Milestone Payment from Ono as Collaborative Program Advances

  7/12/2019

  Schrödinger announced receipt of a milestone payment from Ono Pharmaceutical Co., Ltd. as part of a collaboration leveraging Schrödinger’s advanced computational platform to develop novel therapeutic candidates acting on the therapeutic target selected by Ono.

• Schrödinger Receives Milestone Payment from Sanofi Collaboration

  7/11/2019

  Milestone marks advancement of second drug discovery program under the collaboration

• Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology

  7/9/2019

  Collaboration adds additional program focused on HPK1 inhibitors, potential medicines that could restore proper immune system activity in multiple tumor types

• Schrödinger Bolsters Translational Science Expertise with Leadership Expansion

  6/19/2019

  New hires to lead ADME/PK and Clinical Pharmacology for rapidly advancing internal pipeline programs

• Schrödinger to Present at the Jefferies 2019 Global Healthcare Conference

  5/30/2019

  Schrödinger today announced that Ramy Farid, Ph.D., chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6, 2019 at 11:00 a.m. ET in New York, NY.